Clinical Trials Browser

Phase 3 × Active not recruiting × Melanoma × Clear all

NCT02506153 2026-03-18

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

Phase 3 Active not recruiting

1,301 enrolled 16 charts

Melanoma

NCT02362594 2026-03-05

MK-3475-054

Phase 3 Active not recruiting

1,019 enrolled 16 charts 1 FDA

Melanoma

NCT06346067 2026-02-27

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

Phase 3 Active not recruiting

Melanoma

NCT00003641 2026-02-25

High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

Phase 3 Active not recruiting

1,150 enrolled 6 charts

Melanoma

NCT01274338 2026-02-18

Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

Phase 3 Active not recruiting

1,673 enrolled 19 charts

Melanoma

NCT02224781 2026-02-18

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

Phase 3 Active not recruiting

267 enrolled 8 charts

Melanoma

NCT06054555 2026-01-12

A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma

Phase 3 Active not recruiting

Melanoma

NCT01223248 2025-11-04

Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy

Phase 3 Active not recruiting

DermatologicGynecologicSarcoma

Melanoma, Ovarian Neoplasms, Sarcoma, Pyloric Stenosis, Hypertrophic

NCT04674683 2025-09-24

Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma

Phase 3 Active not recruiting

CNSDermatologic

Brain Neoplasms, Melanoma

NCT05933577 2025-09-24

V940-001

Phase 3 Active not recruiting

Melanoma

NCT05155254 2025-08-28

IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

Phase 3 Active not recruiting

Melanoma

NCT04099251 2025-08-27

CheckMate76K

Phase 3 Active not recruiting

790 enrolled 18 charts 1 FDA

Melanoma

NCT05625399 2025-08-24

RELATIVITY-127

Phase 3 Active not recruiting

Melanoma

NCT05751928 2025-07-08

NEO-MIMAJOR

Phase 3 Active not recruiting

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma

NCT06640530 2025-07-08

UNIVERSE

Phase 3 Active not recruiting

Melanoma

NCT05608291 2025-05-13

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

Phase 3 Active not recruiting

Melanoma, Skin Neoplasms

NCT05732805 2025-02-27

OCTAVA

Phase 3 Active not recruiting

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma

NCT03553836 2024-11-29

KEYNOTE-716

Phase 3 Active not recruiting

976 enrolled 15 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT06320353 2024-03-20

Study сomparing the Efficacy and Safety of RPH-075 and Keytruda® in Patients With Unresectable or Metastatic Skin Melanoma

Phase 3 Active not recruiting

Melanoma, Neoplasms

NCT04949113 2024-03-08

NADINA

Phase 3 Active not recruiting

Melanoma

NCT05270044 2023-11-22

COLUMBUS-AD

Phase 3 Active not recruiting

Melanoma